We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Finding Needles in a Haystack: How One Lab Identified Random Errors in a Large Dataset

By Jen A. Miller (AACC)
Posted on 07 Jul 2023
Lab errors are bound to happen. More...
A mishandled sample here, an equipment failure there—they’re usually not a big deal to fix. But infrequent random errors, especially in high-volume automated tests, can be challenging for clinical laboratorians to identify and rectify in real time. Yet doing so is critical because these problems affect patient care, over and over again.

“As much as we like to believe that errors should not occur in the clinical laboratory, they can and they do,” said Clarence Chan, MD, PhD, a clinical chemistry fellow in the department of pathology at the University of Chicago. “It’s important that we have a rational and objective approach to dealing with these kinds of situations.”

During a roundtable session at the upcoming 2023 AACC Annual Scientific Meeting & Clinical Lab Expo, Chan will present a case study about how his team discovered and investigated random errors that were reoccuring over time. He described the errors as hard to catch even though the lab had quality-control measures in place.

“That’s the whole point of quality control, but sometimes the errors are so sporadic that you don’t always see them,” Chan said. “By coincidence, we had a few primary care doctors asking us about [a couple of results].” That kicked off an investigation into what could be causing such odd and seemingly random recurring errors.

Chan said this case is unique because of its scope–the team reviewed more than 11,000 results over a fairly long period of time–and because it required them to identify a very small fraction of spurious results within that large group. While the details of his experience won’t universally apply to other labs, he hopes participants can learn from how they solved the mystery. This process included brainstorming possible issues and systemically investigating each one until they found the root cause.

Another way labs can benefit from Chan’s insights is hearing how the team applied tools like data analysis and data informatics to their investigation.

“The goal is not to give someone an exact prescription or algorithm of how you deal with these scenarios,” he said. “Every situation will be different.” He added that his team didn’t need high-tech tools to unlock their error-causing mystery. In fact, one of the most important pieces of software they used was Microsoft Excel. “We didn’t have to do any hardcore programming, even though we handle large volumes of data. Understanding how to effectively use Excel, while also recognizing its limits and pitfalls, can also help develop an approach for using more conventional programming software such as R and Python” he said.

The roundtable will empower laboratorians with little to no prior experience in data analytics to gain confidence using large datasets in today’s increasingly digitized healthcare system. This skill is becoming even more critical, given trends towards collecting and analyzing more data across healthcare settings, including clinical laboratories. Globally, “there’s been this push for how do we get that information more efficiently and make more out of it. We’re turning out patient results all the time,” he said. “Not only are you ensuring they're accurate and precise from a technical standpoint, but when there are questions about when things go wrong, how do we get the relevant information?”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.